A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Papers Trust Board - 13 May 2025

Description
Agenda Trust Board – Open Session Date Time Location Chair Apologies In attendance 13/05/202
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-13-May-2025.pdf

Annual ward staffing review January 2025

Description
[5.15] Report to the Trust Board of Directors, 7th January 2025 Title: Ward Staffing Nursing Establishment Review July 2024 – October 2024
Url
/Media/UHS-website-2019/Docs/About-the-Trust/performance/TB-6-monthly-staffing-review-report.pdf

Finance and Performance Reports 2024-25 Month 7 October 2024

Description
Report to the Trust Board of Directors, 29 November 2024 Title: Finance Report 2024-25 Month 7 Sponsor: Ian Howard, Chief Financial Offic
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2024-25-Month-7-October-2024.pdf

Docetaxel-Pertuzumab-Trastuzumab Ver 1.3

Description
Chemotherapy Protocol BREAST CANCER DOCETAXEL-PERTUZUMAB-TRASTUZUMAB This protocol may require funding Regi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Docetaxel-Pertuzumab-Trastuzumab.pdf

Carboplatin-Docetaxel-Trastuzumab

Description
Chemotherapy Protocol BREAST CANCER CARBOPLATIN (AUC6)-DOCETAXEL-TRASTUZUMAB (TCH) Regimen • Breast Cancer – Carboplatin (AUC6)-Docetaxel
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Docetaxel-Trastuzumab.pdf

Capecitabine-Cisplatin-Trastuzumab

Description
Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER CAPECITABINE-CISPLATIN-TRASTUZUMAB Regimen • Gastrointestinal (Upper) Cancer – Cape
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Capecitabine-Cisplatin-Trastuzumab.pdf

Haemtrack - patient information

Description
This factsheet contains information about Haemtrack (an online system developed by the providers of the National Haemophilia Database).
Url
/Media/UHS-website-2019/Patientinformation/Blooddisorders/Haemtrack-902-PIL.pdf

Finance and Performance Reports 2023-24 Month 10 - January 2024

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose: Finance Report 2023-24 Month 10 10.3 Ia
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-10-January-2024.pdf

Finance and Performance Reports 2022-23 Month 2 May 2022

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Issue to be addressed: Finance Report 20
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Finance-and-Performance-Reports-2022-23-Month-2-May-2022.pdf

Cytarabine(SC)-Venetoclax

Description
Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Newly diagn
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf
81 to 90 of 126
Previous … 7 8 9 10 11 … Next